Pair page
GHRP-6 with Tesamorelin
Mechanism-tag overlap and published literature for GHRP-6 and Tesamorelin, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
ghrelin-receptor-agonistgrowth-hormone-secretagogue
fda-approved-ghrh-analogvisceral-adiposity
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying GHRP-6 and Tesamorelin have published these mechanism-level observations. Not a co-administration recommendation.
FDA-approved GHRH analog (Egrifta), originally for HIV-associated lipodystrophy. Used in physician-supervised contexts as the GHRH partner for GHRP-6 in users who want a regulated-quality GHRH alongside research-grade GHRP-6.
Quick facts
GHRP-6
Tesamorelin
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2013 | GHRP-6 | Cabrales A, Gil J, Fernández E, Valenzuela C, Hernández F, García I, Hernández A, Besada V, Reyes O, Padrón G, Berlanga J, Guillén G, González LJ. Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. Eur J Pharm Sci. 2013;48(1-2):… PMID 23159700 | human study |
| 2001 | GHRP-6 | Hataya Y, Akamizu T, Takaya K, et al. A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans. J Clin Endocrinol Metab. 2001;86(9):4552. PMID: 11549709. PMID 11549709 | human study |
| 2001 | GHRP-6 | Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab. 2001;86(3):1169-1174. PMID: 1… PMID 11238504 | human study |
| 1998 | GHRP-6 | Pandya N, DeMott-Friberg R, Bowers CY, Barkan AL, Jaffe CA. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. J Clin Endocrinol Metab. 1998;83(4):1186-1189. PMID: 9543138. (GHRH-GHRP synergy in humans.) PMID 9543138 | human study |
| 2013 | GHRP-6 | Cabrales A, Berlanga J, et al. Cardiotropic effect of GHRP-6: in vivo characterization by echocardiography. Biotecnología Aplicada. 2013;30(4):285-289. (Inotropic effect characterization.) | preclinical, in vivo |
| 2005 | GHRP-6 | Depoortere I, De Winter B, Thijs T, De Man J, Pelckmans P, Peeters T. Comparison of the gastroprokinetic effects of ghrelin, GHRP-6 and motilin in rats in vivo and in vitro. Eur J Pharmacol. 2005;515(1-3):160-168. PMID: 15890335. (Gastric prokinetic mechanism.) PMID 15890335 | preclinical, in vivo |
| 2005 | GHRP-6 | Granado M, Priego T, Martín AI, Villanúa MA, López-Calderón A. Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab. 2005;288(3):E486-492. PMID: 15507534. (GHRP family anti-inflammatory mecha… PMID 15507534 | preclinical, in vivo |
| 1984 | GHRP-6 | Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545. PMID: 6142782. (Foundational GHRP-6 discovery paper.) PMID 6142782 | preclinical, in vivo |
| 2002 | GHRP-6 | Bodart V, Febbraio M, Demers A, McNicoll N, Pohankova P, Perreault A, Sejlitz T, Escher E, Silverstein RL, Lamontagne D, Ong H. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res. 2002;90(8):844-849. PMID: 11988484. (CD36 cardiopr… PMID 11988484 | mechanism / discovery |
| 2001 | GHRP-6 | Bowers CY. Unnatural growth hormone-releasing peptide begets natural ghrelin. J Clin Endocrinol Metab. 2001;86(4):1464-9. PMID: 11297568. (Bowers' personal review of the discovery arc from synthetic to natural ligand.) PMID 11297568 | mechanism / discovery |
| 1999 | GHRP-6 | Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. PMID: 10604470. (Discovery of the natural endogenous ligand of GHS-R1a.) PMID 10604470 | mechanism / discovery |
| 1996 | GHRP-6 | Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. PMID: 8688086. (Cloning of GHS-R1a using GHRP-6 as the radioligand.) PMID 8688086 | mechanism / discovery |
| 2010 | Tesamorelin | Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind place… PMID 20101189 | human trial, Phase 3 |
| — | Tesamorelin | ClinicalTrials.gov. NCT00123253, NCT00435136 (Phase 3 registration); NCT01263717 (JAMA liver fat); NCT02196831 (Lancet HIV NAFLD); NCT00675506 (Arch Neurol cognition). | human trial, Phase 3 |
| 2019 | Tesamorelin | Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PMID: 31611038. PMID 31611038 | human trial |
| 2014 | Tesamorelin | Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. PMID: 25038357. PMID 25038357 | human trial |
| 2005 | Tesamorelin | Falutz J, Allas S, Kotler D, Thompson M, Koutkia P, Albu J, et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS. 2005;19(12):1279-1287. PMID: 16052083. PMID 16052083 | human trial |
| 2004 | Tesamorelin | Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized, controlled trial. JAMA. 2004;292(2):210-218. PMID: 15249570. PMID 15249570 | human trial |
| 2012 | Tesamorelin | Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429.… PMID 22869065 | human study |
| 2011 | Tesamorelin | Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. Clin Infect Dis. 2011;53(11):1150-1158. PMID: 22016502. PMID 22016502 | human study |
| 2008 | Tesamorelin | Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728. PMID: 18690162. PMID 18690162 | human study |
| 2007 | Tesamorelin | Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PMID: 18057338. PMID 18057338 | human study |
| 2011 | Tesamorelin | Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071-1091. PMID: 21668043. PMID 21668043 | review |
| 2026 | Tesamorelin | World Anti-Doping Agency. The 2026 Prohibited List. Section S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics. wada-ama.org. | regulatory / registry |
Related pair pages
More research context
Frequently asked
Have GHRP-6 and Tesamorelin been studied together?
Researchers have published mechanistic-level co-administration discussion of GHRP-6 and Tesamorelin. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do GHRP-6 and Tesamorelin share?
GHRP-6 and Tesamorelin do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of GHRP-6 and Tesamorelin?
GHRP-6: Investigational (Category 2 bulk). Tesamorelin: Approved (2010). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on GHRP-6 and Tesamorelin?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the GHRP-6 profile and the Tesamorelin profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026